Principal Investigator - Prof Dame Lesley Fallowfield
Co-Investigator - Prof Val Jenkins
Funder: Boehringer Ingelheim GmBH
Funder: Boehringer Ingelheim GmBH
To determine the 'value' of PFS to patients with metastatic cancer:
- 1. Patient understanding of therapeutic intent
- 2. Their goals and priorities
- 3.Trade-offs between burdens/toxicities/QoL and Survival (PFS and OS)
- 4. Patient characteristics that under-pin decisions about treamtment options
- 5. Association of PFS improvement and/or deterioration with QoL and underlying mechanism
- 6. Association of PFS improvement and or deterioration of psychological well-being.
Progression Free Survival (PFS) is commonly used as an endpoint in clinical trials of novel cancer therapies. This study aims to find out what this means for patients. What they understand about and expect from these treatments and if the benefits from the treatment controlling the cancer make it worth any side effects they could or do experience.
Current Stage:
Archived
Publication
The value of progression-free survival to patients with advanced-stage cancer Find it here Publication
Therapeutic aims of drugs offering only Progression Free Survival are misunderstood by patients, and oncologists may be overly optimistic about likely benefits Find it here Publication
Do drugs offering only PFS maintain quality of life sufficiently from a patient's perspective? Results from AVALPROFS (Assessing the 'VALue' to patients of PROgression Free Survival) study Find it here Poster
Assessing the VALue of PROgression Free Survival (AVALPROFS) Find it here Poster
Assessing the VALue to patients of PROgression Free Survival (AVALPROFS) Quality of Life Results Find it here Poster
Hoping against hope: Are patients' expectations and understanding about
therapeutic aims of novel drugs similar to their oncologists? Find it here Report
Further Analyses from AVALPROFS (Trade off questions and Quality of Life) Find it here